NasdaqCM - Nasdaq Real Time Price USD

Agenus Inc. (AGEN)

5.37

-0.18

(-3.24%)

At close: June 10 at 4:00:01 PM EDT

5.29

-0.08

(-1.49%)

Pre-Market: 4:30:21 AM EDT

Agenus Announces Virtual Annual Shareholders Meeting

LEXINGTON, Mass., June 10, 2025--Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 17, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.

Business Wire 15 hours ago

AGEN
-3.24%
Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to Trade

The mean of analysts' price targets for Agenus (AGEN) points to a 26.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks 6 days ago

AGEN
-3.24%
Agenus and Zydus sign agreements for botensilimab and balstilimab

Agenus will give Zydus an exclusive licence for the development and commercialisation of BOT and BAL in Sri Lanka and India.

Pharmaceutical Technology 6 days ago

AGEN
-3.24%
Agenus to Sell US Manufacturing Facilities to Zydus Lifesciences

Agenus (AGEN) has agreed to sell its biologics manufacturing facilities in the US to Zydus Lifescien

PRÉMIUM
MT Newswires 7 days ago

AGEN
-3.24%
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US

LEXINGTON, Mass., June 03, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE: ZYDUSLIFE), including its subsidiaries/affiliates, hereafter referred to as "Zydus," designed to accelerate clinical development, scale global manufacturing, and expand patient access to botensilimab and balstilimab (BOT/BAL).

Business Wire 7 days ago

AGEN
-3.24%
Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer

LEXINGTON, Mass., May 30, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and persistent T cell immune response in microsatellite stable (MSS), or mismatch repair proficient (pMMR), metastatic colorectal cancer (mCRC)—a tumor type traditionally resistant to immunotherapy and representing approximatel

Business Wire 11 days ago

AGEN
-3.24%
Despite Fast-paced Momentum, Agenus (AGEN) Is Still a Bargain Stock

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks 22 days ago

AGEN
-3.24%
Agenus says expanded MSS mCRC cohort data to be presented at ESMO GI

Agenus (AGEN) announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab in patients with microsatellite stable metastatic colorectal cancer will be presented at the 2025 European Society for Medical Oncology Gastrointestinal Cancers Congress in Barcelona, Spain. A poster presentation will feature updated findings from an expanded cohort of 123 patients, incorporating additional participants and extended follow-up to further assess clinical activity of the combinat

TipRanks 25 days ago

AGEN
-3.24%
Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

LEXINGTON, Mass., May 15, 2025--Agenus Inc. ("Agenus" or the Company") (NASDAQ: AGEN), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Barcelona, Spain. A poster presentation will feature updated findings from an expanded cohort of 123 pa

Business Wire 26 days ago

AGEN
-3.24%
Agenus Inc (AGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges

Agenus Inc (AGEN) reports a narrowed net loss and strategic advancements despite revenue decline and cash pressure in Q1 2025.

GuruFocus.com 29 days ago

AGEN
-3.24%
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of 36.02% and 14.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 29 days ago

AGEN
-3.24%
Agenus: Q1 Earnings Snapshot

LEXINGTON, Mass. AP) — Agenus Inc. AGEN) on Monday reported a loss of $26.4 million in its first quarter.

Associated Press Finance 29 days ago

AGEN
-3.24%
Agenus Reports Q1 2025 Financial Results and Key Business Updates

LEXINGTON, Mass., May 12, 2025--Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) program.

Business Wire 29 days ago

AGEN
-3.24%
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

LEXINGTON, Mass., May 12, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation today announced that Dr. Richard M. Goldberg, an internationally recognized expert in gastrointestinal (GI) cancer treatment and research, has joined the company as Chief Development Officer. In this role, Dr. Goldberg will lead efforts to advance the botensilimab/balstilimab (BOT/BAL) program for patients and guide the company’s regulatory and development strategy as it prepares to re-engage globa

Business Wire 29 days ago

AGEN
-3.24%
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.

Zacks last month

ANIP

AGEN
-3.24%
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

AGEN
-3.24%

ADCT
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

LEXINGTON, Mass., April 29, 2025--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.

Business Wire last month

AGEN
-3.24%
Agenus’ BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

LEXINGTON, Mass., April 28, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. This represents the third clinical study evaluating botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting, with outcomes reported in mismatch repair–proficient (pMMR/MSS) and mismatch repair–deficien

Business Wire last month

AGEN
-3.24%
Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

LEXINGTON, Mass., April 25, 2025--Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab (BOT) in combination with balstilimab (BAL). These findings are being presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. The HCC cohort comprised patients with difficult-to-treat disease who had progressed following

Business Wire last month

AGEN
-3.24%
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

LEXINGTON, Mass., April 23, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced three upcoming presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago, Illinois. A poster presentation will highlight new translational data monitoring induced T-cell dynamics from the botensilimab and balstilimab (BOT/BAL) program in mismatch repair–proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal ca

Business Wire last month

AGEN
-3.24%

Performance Overview

Return	AGEN	S&P 500 (^GSPC)
AIF	+95.99%	+2.67%
1-Year	-68.72%	+12.65%
3-Year	-81.26%	+54.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Agenus Inc. (AGEN)

Agenus Announces Virtual Annual Shareholders Meeting

Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to Trade

Agenus and Zydus sign agreements for botensilimab and balstilimab

Agenus to Sell US Manufacturing Facilities to Zydus Lifesciences

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US

Agenus Presents New Data at ASCO Highlighting Botensilimab’s Immune Activation in MSS Colorectal Cancer

Despite Fast-paced Momentum, Agenus (AGEN) Is Still a Bargain Stock

Agenus says expanded MSS mCRC cohort data to be presented at ESMO GI

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

Agenus Inc (AGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges

Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates

Agenus: Q1 Earnings Snapshot

Agenus Reports Q1 2025 Financial Results and Key Business Updates

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Agenus’ BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Performance Overview